Investor Relations

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack applies its systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has six targeted therapeutic oncology candidates in clinical development.

View all »   RSSRecent Releases

Apr 21, 2015
First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients

Apr 20, 2015
Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer

Mar 26, 2015
Merrimack to Highlight Extensive Oncology Pipeline at the 2015 American Association for Cancer Research Annual Meeting

Feb 26, 2015
Merrimack Pharmaceuticals Reports Fourth Quarter 2014 Financial Results

Stock Quote (NASDAQ: MACK)

Price:
13.42

Change:
- 0.25

Day High:
13.77

Day Low:
13.42

Volume:
756,400

4:00 PM ET on Apr 24, 2015
Delayed ~20 min. By eSignal.

Shareholder Tools